Yanyang Biotech Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Series A1
- Investors
-
6
Yanyang Biotech General Information
Description
Operator of a biotechnology company focusing on the R&D of innovative microbial drugs. The company applies its core technology to the screening of anaerobic microorganisms, bacterial drug evaluation and storage and transportation of live bacteria, and its self-developed "KAL-001" series of live multi-linkage bacteria drugs have entered the stage of clinical trials.
Contact Information
Website
www.scyysw.cnCorporate Office
- Number 13, Section 4, Renmin South Road
- Wuhou District
- Chengdu, Sichuan
- China
Corporate Office
- Number 13, Section 4, Renmin South Road
- Wuhou District
- Chengdu, Sichuan
- China
Yanyang Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A1) | 26-Jan-2026 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 26-Sep-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 01-Aug-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 14-Sep-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 01-Jul-2021 | $1.43M | Completed | Generating Revenue | ||
| 1. Seed Round | 01-Jan-2020 | $1.43M | $1.43M | Completed | Startup |
Yanyang Biotech Patents
Yanyang Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4644531-A1 | Probiotic composition for preventing and treating anti-tumor treatment-related diarrhea and use thereof | Pending | 06-Jun-2023 | ||
| EP-4644531-A4 | Probiotic composition for preventing and treating anti-tumor treatment-related diarrhea and use thereof | Pending | 06-Jun-2023 | ||
| US-20260115237-A1 | Probiotic composition for preventing and treating anti-tumor treatment-related diarrhea and use thereof | Pending | 06-Jun-2023 | ||
| WO-2024251031-A1 | Probiotic composition for preventing and treating anti-tumor treatment-related diarrhea and use thereof | Inactive | 06-Jun-2023 | ||
| JP-7942701-B2 | Probiotic composition for preventing and treating antitumor-related diarrhea and its use | Active | 06-Jun-2023 | C12N1/20 |
Yanyang Biotech Signals
Yanyang Biotech Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Wedge Industrial Company | Corporation | Minority | ||
| Chengdu Innovation Venture Capital | Growth/Expansion | Minority | ||
| Dalton Venture | Venture Capital | Minority | ||
| Shenzhen CDF Capital | Venture Capital | Minority | ||
| Chengdu Bio-Town Investment | Government | Minority |
Yanyang Biotech FAQs
-
When was Yanyang Biotech founded?
Yanyang Biotech was founded in 2019.
-
Where is Yanyang Biotech headquartered?
Yanyang Biotech is headquartered in Chengdu, China.
-
What is the size of Yanyang Biotech?
Yanyang Biotech has 9 total employees.
-
What industry is Yanyang Biotech in?
Yanyang Biotech’s primary industry is Drug Discovery.
-
Is Yanyang Biotech a private or public company?
Yanyang Biotech is a Private company.
-
What is Yanyang Biotech’s current revenue?
The current revenue for Yanyang Biotech is .
-
How much funding has Yanyang Biotech raised over time?
Yanyang Biotech has raised $16.3M.
-
Who are Yanyang Biotech’s investors?
Wedge Industrial Company, Chengdu Innovation Venture Capital, Dalton Venture, Shenzhen CDF Capital, and Chengdu Bio-Town Investment are 5 of 6 investors who have invested in Yanyang Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process